| scholarly article | Q13442814 |
| P356 | DOI | 10.1021/ML400186Z |
| P8608 | Fatcat ID | release_regimxhbmvfzlpexosvyrvaml4 |
| P932 | PMC publication ID | 4027368 |
| P698 | PubMed publication ID | 24900747 |
| P50 | author | Ryo Okuyama | Q72967848 |
| P2093 | author name string | Ming Yu | |
| Yi Chen | |||
| Leping Li | |||
| Xiaolin Hao | |||
| Satoshi Shibuya | |||
| Hui Tian | |||
| Run Zhuang | |||
| Futoshi Nara | |||
| Yasuyuki Ogawa | |||
| Yi-Jyun Lin | |||
| Yongjae Kim | |||
| Sarah Lively | |||
| Zice Fu | |||
| Masanori Izumi | |||
| Jeff D Reagan | |||
| Julio Medina | |||
| Nobuaki Watanabe | |||
| Qingxiang Liu | |||
| Alykhan Motani | |||
| Angela Fu | |||
| Yumei Xiong | |||
| Narihiro Toda | |||
| Peter Fan | |||
| Mike Lizarzaburu | |||
| Michiko Murakoshi | |||
| Kozo Oda | |||
| Shauna Lawlis | |||
| P2860 | cites work | The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 |
| Sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus: a review | Q34168385 | ||
| The role of sulphonylureas in the management of type 2 diabetes mellitus | Q35807254 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes | Q37481309 | ||
| The therapeutic potential of GPR119 agonists for type 2 diabetes | Q37980173 | ||
| Lipophilicity in drug discovery | Q38028532 | ||
| Novel metabolic bioactivation mechanism for a series of anti-inflammatory agents (2,5-diaminothiophene derivatives) mediated by cytochrome p450 enzymes. | Q43041998 | ||
| Risk of macrovascular and microvascular complications in Type 2 diabetes: results of longitudinal study design | Q44070306 | ||
| (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes | Q45212807 | ||
| Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes. | Q48621489 | ||
| Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus. | Q48628829 | ||
| P433 | issue | 8 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 790-794 | |
| P577 | publication date | 2013-06-17 | |
| P1433 | published in | ACS Medicinal Chemistry Letters | Q2819061 |
| P1476 | title | Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes | |
| P478 | volume | 4 |
| Q26830274 | Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development |
| Q55262651 | Differential role of GPR142 in tryptophan-mediated enhancement of insulin secretion in obese and lean mice. |
| Q49598911 | Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes |
| Q35178871 | Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist |
| Q35996954 | GPR142 Agonists Stimulate Glucose-Dependent Insulin Secretion via Gq-Dependent Signaling |
| Q36056936 | GPR142 Controls Tryptophan-Induced Insulin and Incretin Hormone Secretion to Improve Glucose Metabolism |
| Q52673362 | GPR142 prompts glucagon-like Peptide-1 release from islets to improve β cell function. |
| Q59548972 | Germline RAD51B truncating mutation in a family with cutaneous melanoma |
| Q90260620 | Glucagon-Like Peptide-1: Actions and Influence on Pancreatic Hormone Function |
| Q50964984 | Insights into unbound-bound states of GPR142 receptor in a membrane-aqueous system using molecular dynamics simulations. |
| Q90429528 | Leveraging the Gut to Treat Metabolic Disease |
| Q92948184 | Sustainable Synthetic Approach for (Pyrazol-4-ylidene)pyridines By Metal Catalyst-Free Aerobic C(sp2)-C(sp3) Coupling Reactions between 1-Amino-2-imino-pyridines and 1-Aryl-5-pyrazolones |
| Q48253186 | Synthesis and Pharmacological Activities of Pyrazole Derivatives: A Review |
| Q63379404 | The aromatic amino acid sensor GPR142 controls metabolism through balanced regulation of pancreatic and gut hormones |
| Q64280793 | The functional impact of G protein-coupled receptor 142 (Gpr142) on pancreatic β-cell in rodent |
Search more.